Figure 5.

NAVIGATER enhances the sensitivity of downstream detection methods. (A, B) ddPCR of samples from pancreatic cancer patients containing KRAS mutants (Supplementary Table S2): (A) Fraction of droplets reporting mutant alleles in the absence of enrichment (control), once enriched, and twice enriched. (B) Increase in mutant allele frequency after NAVIGATER enrichment. (C) PNA-PCR’s amplification curves of pancreatic cancer patients’ samples before (i) and after (ii) NAVIGATER, and amplification threshold time as a function of MAF (iii). (D) PNA-LAMP of spiked RNA samples before and after NAVIGATER carried out with a minimally-instrumented, electricity-free Smart-Connected Cup (SCC) (23). (E) Sanger sequencing before and after NAVIGATER of samples spiked with RNA extracted from cell lines. All the controls were pre-processed in the absence of TtAgo. N = 3